Paul E. Makidon
Impact in
- Pharmaceutical Science top 2%
- Advanced Drug Delivery Systems
- Immunology top 10%
- Immunotherapy and Immune Responses
- Immune Response and Inflammation
Papers in
-
- Immunotherapy and Immune Responses 4
- Immune Response and Inflammation 4
-
- Glycosylation and Glycoproteins Research 1
- Co-authors
- James R. Baker (15 shared papers)Anna U. Bielinska (8 shared papers)Katarzyna Janczak (6 shared papers)Luz P. Blanco (5 shared papers)Jeffrey J. Landers (4 shared papers)Zhengyi Cao (6 shared papers)Michael Beer (3 shared papers)John J. LiPuma (3 shared papers)
- Journals
- Human Vaccines & Immunotherapeutics (2 papers)PLoS ONE (2 papers)Nanomedicine (2 papers)Journal of Aerosol Medicine and Pulmonary Drug Delivery (1 paper)Medical Microbiology and Immunology (1 paper)
- Partner nations
- United StatesNetherlandsChina
In The Last Decade
Paul E. Makidon
19 papers receiving 714 citations
Peers
Comparison fields: 5 of 95
- Pharmaceutical Science 146
- Immunology 243
- Endocrinology 40
- Microbiology 46
- Infectious Diseases 100
Countries citing papers authored by Paul E. Makidon
This map shows the geographic impact of Paul E. Makidon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Makidon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Makidon more than expected).
Fields of papers citing papers by Paul E. Makidon
This network shows the impact of papers produced by Paul E. Makidon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Makidon. The network helps show where Paul E. Makidon may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul E. Makidon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 116 | |
| 2 | 2007 | 101 | |
| 3 | 2013 | 56 | |
| 4 | 2009 | 54 | |
| 5 | 2010 | 48 | |
| 6 | 2014 | 48 | |
| 7 | 2008 | 45 | |
| 8 | 2014 | 45 | |
| 9 | 2012 | 42 | |
| 10 | 2009 | 39 | |
| 11 | 2015 | 33 | |
| 12 | 2022 | 26 | |
| 13 | 2017 | 24 | |
| 14 | 2015 | 21 | |
| 15 | 2012 | 13 | |
| 16 | 2013 | 11 | |
| 17 | 2016 | 8 | |
| 18 | 2005 | 6 | |
| 19 | Effect of Chronic Uremia on the Cell Surface Expression of B7 Family Costimulatory Molecules in an HLA-A2 Transgenic Mouse Model of Chronic Kidney Disease. | 2015 | 4 |
About Paul E. Makidon
Paul E. Makidon is a scholar working on Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, Pharmaceutical Science and Epidemiology, having authored 19 papers that have together received 740 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (4 papers), Advanced Drug Delivery Systems (4 papers), Immune Response and Inflammation (4 papers), Pneumonia and Respiratory Infections (2 papers), Cystic Fibrosis Research Advances (2 papers), Respiratory viral infections research (2 papers), Glycosylation and Glycoproteins Research (1 paper) and Diabetes and associated disorders (1 paper). The work is most often cited by research in Pharmaceutical Science (146 citations), Immunology (243 citations), Endocrinology (40 citations), Microbiology (46 citations) and Infectious Diseases (100 citations). Paul E. Makidon has collaborated with scholars based in United States, Netherlands and China. Frequent co-authors include James R. Baker, Anna U. Bielinska, Katarzyna Janczak, Luz P. Blanco, Jeffrey J. Landers, Zhengyi Cao, Michael Beer, John J. LiPuma, Sivaprakash Rathinavelu and Douglas M. Smith. Their work appears in journals such as Human Vaccines & Immunotherapeutics, PLoS ONE, Nanomedicine, Journal of Aerosol Medicine and Pulmonary Drug Delivery and Medical Microbiology and Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.